CRVS vs. CRBP, ORGS, TXMD, PPBT, YMTX, ELDN, CKPT, LPTX, RNXT, and SLS
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Corbus Pharmaceuticals (CRBP), Orgenesis (ORGS), TherapeuticsMD (TXMD), Purple Biotech (PPBT), Yumanity Therapeutics (YMTX), Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Leap Therapeutics (LPTX), RenovoRx (RNXT), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.
Corvus Pharmaceuticals vs.
Corvus Pharmaceuticals (NASDAQ:CRVS) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, community ranking, analyst recommendations, valuation, risk and profitability.
Corvus Pharmaceuticals' return on equity of -56.80% beat Corbus Pharmaceuticals' return on equity.
Corvus Pharmaceuticals presently has a consensus target price of $3.17, suggesting a potential upside of 247.99%. Corbus Pharmaceuticals has a consensus target price of $3.00, suggesting a potential downside of 58.73%. Given Corvus Pharmaceuticals' higher probable upside, research analysts plainly believe Corvus Pharmaceuticals is more favorable than Corbus Pharmaceuticals.
47.5% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.7% of Corbus Pharmaceuticals shares are owned by institutional investors. 29.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 8.2% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Corbus Pharmaceuticals has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals received 143 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. Likewise, 68.72% of users gave Corbus Pharmaceuticals an outperform vote while only 63.86% of users gave Corvus Pharmaceuticals an outperform vote.
In the previous week, Corvus Pharmaceuticals had 8 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 8 mentions for Corvus Pharmaceuticals and 0 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.89 beat Corvus Pharmaceuticals' score of 0.26 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.
Corvus Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
Summary
Corbus Pharmaceuticals beats Corvus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
